{"id":10100,"date":"2026-04-01T06:13:37","date_gmt":"2026-04-01T11:13:37","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10100"},"modified":"2026-04-01T06:17:26","modified_gmt":"2026-04-01T11:17:26","slug":"nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","title":{"rendered":"Nanoscope Therapeutics nombra a Paul Hallen, veterano de la industria oftalmol\u00f3gica, como director de operaciones para impulsar la preparaci\u00f3n comercial global."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Ejecutivo veterano en oftalmolog\u00eda con m\u00e1s de 30 a\u00f1os de experiencia en I+D, fabricaci\u00f3n, calidad, estrategia comercial y liderazgo de franquicias.<\/em><\/h3>

Exvicepresidente y director global de Retina en Alcon, con amplia experiencia en la creaci\u00f3n y expansi\u00f3n de franquicias oftalmol\u00f3gicas a nivel mundial.<\/em><\/h3>

Este nombramiento refuerza el liderazgo operativo a medida que Nanoscope avanza con MCO-010 (MOGENRY\u2122) hacia la presentaci\u00f3n de la solicitud de licencia biol\u00f3gica (BLA) y su posible comercializaci\u00f3n.<\/em><\/h3>

DALLAS<\/span>,\u00a01 de abril de 2026<\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy el nombramiento de Paul Hallen como Director de Operaciones.<\/p>

El Sr. Hallen cuenta con m\u00e1s de 30 a\u00f1os de amplia experiencia en liderazgo en el sector oftalmol\u00f3gico, abarcando marketing, ventas, fabricaci\u00f3n, calidad, investigaci\u00f3n y desarrollo, y estrategia empresarial. Anteriormente, fue vicepresidente y director global de Retina en Alcon, donde contribuy\u00f3 a liderar una de las principales divisiones de retina del sector. Tambi\u00e9n desempe\u00f1\u00f3 el cargo de vicepresidente de I+D, apoyando el desarrollo interno y las actividades de adquisiciones externas en todas las unidades de negocio de Alcon. El Sr. Hallen tambi\u00e9n fue miembro del consejo de administraci\u00f3n de US Retina.<\/p>

Como director de operaciones, el Sr. Hallen liderar\u00e1 las operaciones globales de Nanoscope, incluyendo la preparaci\u00f3n comercial, la cadena de suministro y la ejecuci\u00f3n interfuncional, a medida que la empresa avanza con MCO-010 (MOGENRY\u2122) hacia una posible aprobaci\u00f3n regulatoria y su lanzamiento.<\/p>

\u201cPaul es un l\u00edder muy respetado en oftalmolog\u00eda, con una excepcional combinaci\u00f3n de experiencia t\u00e9cnica, operativa y comercial\u201d, declar\u00f3 Sulagna Bhattacharya, cofundadora y directora ejecutiva de Nanoscope Therapeutics. \u201cConocemos a Paul y hemos colaborado estrechamente con \u00e9l durante muchos a\u00f1os, y su nombramiento llega en un momento crucial, ya que seguimos prepar\u00e1ndonos para la posible comercializaci\u00f3n de MOGENRY. Su experiencia en retina, desarrollo de productos y planificaci\u00f3n de lanzamientos globales ser\u00e1 invaluable a medida que trabajamos para llevar nuestras terapias de restauraci\u00f3n de la visi\u00f3n a pacientes de todo el mundo\u201d.\u201d<\/p>

\u201cMe entusiasma unirme a Nanoscope en una etapa tan importante de su desarrollo\u201d, declar\u00f3 Paul Hallen, director de operaciones de Nanoscope Therapeutics. \u201cLa plataforma MOGENRY de Nanoscope representa un enfoque fundamentalmente diferente con el potencial de restaurar la visi\u00f3n en pacientes con enfermedades retinianas graves. Espero con inter\u00e9s trabajar con el equipo para impulsar MOGENRY hacia su posible aprobaci\u00f3n y para respaldar la preparaci\u00f3n operativa y comercial de la empresa para la siguiente fase de crecimiento\u201d.\u201d<\/p>

Avanzando hacia la comercializaci\u00f3n
<\/b>Nanoscope contin\u00faa impulsando los avances cl\u00ednicos, regulatorios y de producci\u00f3n a gran escala de MOGENRY para la retinosis pigmentaria, incluyendo el progreso de su solicitud de licencia para productos biol\u00f3gicos en Estados Unidos. La compa\u00f1\u00eda tambi\u00e9n ha consolidado una creciente base regulatoria global para MOGENRY, con las designaciones de medicamento hu\u00e9rfano, v\u00eda r\u00e1pida y RMAT en Estados Unidos, las designaciones Sakigake y medicamento hu\u00e9rfano en Jap\u00f3n, cinco designaciones de medicamento hu\u00e9rfano de la EMA para distrofias retinianas hereditarias y, m\u00e1s recientemente, una designaci\u00f3n de medicamento hu\u00e9rfano para distrofias retinianas hereditarias en Arabia Saudita. Estos logros reflejan la expansi\u00f3n de la trayectoria regulatoria internacional de la compa\u00f1\u00eda a medida que avanza en la planificaci\u00f3n de su comercializaci\u00f3n en mercados globales clave.<\/p>

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0A principios de 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience a principios de 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Nanoscope Therapeutics, Inc.
+1 (817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Veteran\u00a0ophthalmology executive with over 30 years of experience spanning R&D, manufacturing, quality, commercial strategy, and franchise leadership Former Vice President and Global Head of Retina at Alcon, with deep experience building and scaling global ophthalmic franchises Appointment strengthens operational leadership as Nanoscope advances MCO-010 (MOGENRY\u2122) toward BLA submission and potential commercialization DALLAS,\u00a0April 1, 2026\u00a0 \u2014 […]<\/p>\n","protected":false},"author":1,"featured_media":10101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T11:13:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T11:17:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics nombra a Paul Hallen, veterano de la industria oftalmol\u00f3gica, como director de operaciones para impulsar su preparaci\u00f3n comercial global.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-04-01T11:13:37+00:00","article_modified_time":"2026-04-01T11:17:26+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"wordCount":733,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","url":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","name":"Nanoscope Therapeutics nombra a Paul Hallen, veterano de la industria oftalmol\u00f3gica, como director de operaciones para impulsar su preparaci\u00f3n comercial global.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10100"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10100\/revisions"}],"predecessor-version":[{"id":10105,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10100\/revisions\/10105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10101"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}